

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM322195

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
PDI, Inc.		10/31/2014	CORPORATION: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	SWK Funding LLC, as agent
<b>Street Address:</b>	15770 Dallas Parkway, Suite 1290
<b>City:</b>	Dallas
<b>State/Country:</b>	TEXAS
<b>Postal Code:</b>	75248
<b>Entity Type:</b>	LIMITED LIABILITY COMPANY: DELAWARE

## PROPERTY NUMBERS Total: 11

Property Type	Number	Word Mark
Serial Number:	86130866	INTERPACE DIAGNOSTICS
Serial Number:	76630045	PDI
Serial Number:	76630047	
Serial Number:	76630046	PDI
Serial Number:	86227209	PD ONE REP
Serial Number:	85930489	THE MEDICAL BUZZ
Serial Number:	85929050	THE MEDICAL BAG
Serial Number:	85930510	WHAT KILLED 'EM
Serial Number:	85930412	DESPICABLE DOCTORS
Serial Number:	85930420	COMIC SEIZURE
Serial Number:	85971374	HCP ECOSYSTEM

## CORRESPONDENCE DATA

Fax Number: 2149649501

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 214.964.9459

Email: ryan.magee@hklaw.com

Correspondent Name: Ryan Magee

Address Line 1: Holland &amp; Knight LLP

Address Line 2: 200 Crescent Court, Suite 1600

Address Line 4: Dallas, TEXAS 75201

TRADEMARK

<b>ATTORNEY DOCKET NUMBER:</b>	136144.00018/MADREWS
<b>NAME OF SUBMITTER:</b>	Ryan Magee
<b>SIGNATURE:</b>	/Ryan Magee/
<b>DATE SIGNED:</b>	11/04/2014

**Total Attachments: 12**

source=Interpace IP Security Agreement REDACTED (Interpace)#page1.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page2.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page3.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page4.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page5.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page6.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page7.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page8.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page9.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page10.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page11.tif  
source=Interpace IP Security Agreement REDACTED (Interpace)#page12.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of October 31, 2014 (as may be amended, restated, supplemented, or otherwise modified from time to time, this “**Agreement**”), made by Interpace Diagnostics, LLC, a Delaware limited liability company, Group DCA, LLC, a Delaware limited liability company, JS GENETICS, INC., a Delaware corporation, and PDI, INC., a Delaware corporation (each a “**Grantor**” and collectively the “**Grantors**”), in favor of SWK FUNDING LLC, a Delaware limited liability company, as collateral agent (in such capacity, “**Agent**”) for the Lenders (as defined below) party to the Credit Agreement (as defined below).

### **W I T N E S S E T H:**

WHEREAS, pursuant to that certain Credit Agreement, dated on or about the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), by and among PDI, INC., a Delaware corporation (“**Borrower**”), Agent and the financial institutions party thereto from time to time as lenders (each a “**Lender**” and collectively, the “**Lenders**”), Agent and Lenders have agreed to make certain financial accommodations available to Borrower, and Borrower has granted a security interest to Agent, for the benefit of Lenders, in, among other things, all right, title and interest of Borrower in, to and under all of Borrower’s Intellectual Property (as defined below), whether now existing or hereafter arising or acquired as security for the Obligations;

WHEREAS, the Borrower is affiliated with each Grantor. The Borrower and the other Grantors are engaged in interrelated businesses, and each Grantor will derive substantial direct and indirect benefit from extensions of credit under the Credit Agreement; and

WHEREAS, Each Grantor is the owner of the entire right, title and interest in, to and under the Intellectual Property listed on Schedule I hereto as applicable.

NOW, THEREFORE, in consideration of the premises and to induce Agent and Lenders to enter into the Credit Agreement, each Grantor hereby agrees with Agent as follows:

#### **1. Defined Terms.**

(a) Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement.

(b) Definitions of Certain Terms Used Herein. As used herein, the following terms shall have the following meanings:

“**Copyrights**” shall mean all of each Grantor’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right, title, and interest in and to: (i) copyrights, rights and interests in copyrights, works protectable by copyright, all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Copyright Office or in any similar office or agency of the United States, any State thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; and (ii) all renewals of any of the foregoing.

“**Copyright Licenses**” shall mean all written agreements naming any Grantor as licensor or licensee, granting any right under any Copyright, including the grant of rights to manufacture,

distribute, exploit and sell materials derived from any Copyright (other than agreements relating to widely-available software subject to “shrink-wrap” or “click-through” software licenses).

“**Credit Agreement**” shall have the meaning assigned to such term in the recitals of this Agreement.

“**Intellectual Property**” shall mean all present and future: trade secrets, know-how and other proprietary information; Trademarks, internet domain names, service marks, trade dress, trade names, business names, designs, logos, slogans (and all translations, adaptations, derivations and combinations of the foregoing) indicia and other source and/or business identifiers, and the goodwill of the business relating thereto and all registrations or applications for registrations which have heretofore been or may hereafter be issued thereon throughout the world; Copyrights (including Copyrights for computer programs, but excluding commercially available off-the-shelf software and any Intellectual Property rights relating thereto) and all tangible and intangible property embodying the Copyrights, unpatented inventions (whether or not patentable); Patents; industrial design applications and registered industrial designs; license agreements related to any of the foregoing and income therefrom, books, records, writings, computer tapes or disks, flow diagrams, specification sheets, computer software, source codes, object codes, executable code, data, databases and other physical manifestations, embodiments or incorporations of any of the foregoing; the right to sue for all past, present and future infringements of any of the foregoing; all other intellectual property; and all common law and other rights throughout the world in and to all of the foregoing.

“**IP Collateral**” shall have the meaning assigned to such term in Section 2 hereof.

“**Licenses**” shall mean, collectively, the Trademark Licenses, the Patent Licenses, and the Copyright Licenses.

“**Patents**” shall mean all of each Grantor’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right, title and interest in and to: (i) all patents, patent applications, inventions, invention disclosures and improvements, and all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; and (ii) the reissues, divisions, continuations, renewals, extensions and continuations-in-part of any of the foregoing.

“**Patent Licenses**” shall mean all agreements, whether written or oral, providing for the grant by or to any Grantor of any right to manufacture, develop, market, use or sell any products derived, in whole or in part, from any invention covered by a Patent or any similar agreement related to any other use of any invention covered by a Patent.

“**Trademarks**” shall mean all of each Grantor’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right, title, and interest in and to: (i) all of each Grantor’s (or if referring to another Person, such other Person’s) trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos, other business identifiers, all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; (ii) all renewals thereof; and (iii) all designs and general intangibles of a like nature.

“**Trademark Licenses**” shall mean, collectively, each agreement, whether written or oral, providing for the grant by or to any Grantor of any right to use any Trademark.

(c) **Other Definitional Provisions.**

(i) The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and section and paragraph references are to this Agreement unless otherwise specified.

(ii) The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms.

2. **Grant of Security Interest.** To secure the payment and performance of the Obligations, each Grantor hereby confirms and acknowledges that it has granted (and, to the extent not previously granted under the Guarantee and Collateral Agreement, does hereby grant) to Agent, for the benefit of Lenders, a lien and security interest in such Grantor’s entire right, title and interest in its Intellectual Property and all proprietary rights relating to or arising from such Intellectual Property, in each case whether now owned or hereafter acquired by such Grantor, and including, without limitation, such Grantor’s right, title and interest in and to the Intellectual Property and proprietary rights identified on Schedule I attached hereto and made a part hereof, and the right to sue for past, present and future infringements and dilutions, and all rights corresponding thereto throughout the world, and the entire goodwill of such Grantor’s business connected with and symbolized by such Intellectual Property and all income, fees, royalties, proceeds and other payments at any time due or payable with respect to any of the foregoing (referred to collectively as the “**IP Collateral**”); provided, that the IP Collateral shall not include the Excluded Property (as defined in the Guarantee and Collateral Agreement).

3. **Protection of Intellectual Property by Grantors.** Each Grantor shall, at its sole cost, expense and risk, in connection with the operation of its business, comply with the requirements set forth in Section 5.7 of the Guarantee and Collateral Agreement in respect to the Intellectual Property.

4. **Representations and Warranties.** Each Grantor represents and warrants that:

(a) Schedule I is a true, correct and complete list of all registered or applied-for Intellectual Property in which such Grantor purports to have an ownership or license interest.

(b) Such Grantor has the legal right and authority to enter into this Agreement and perform its terms.

(c) If such Grantor amends its name, such Grantor shall provide copies of such amendment documentation to Agent and shall re-register such Grantor’s Intellectual Property with the appropriate Governmental Authority and shall execute and deliver such agreements or documentation as Agent shall request to maintain a perfected first priority security interest in such Intellectual Property subject to Permitted Liens.

5. **No Violation of Credit Agreement.** The representations, warranties or covenants contained herein are supplemental to those representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any other Loan Document.

**6. Agreement Applies to Future Intellectual Property.**

(a) The provisions of this Agreement shall automatically apply to any such additional property or rights described in Section 2 above, all of which shall be deemed to be and treated as “IP Collateral” within the meaning of this Agreement.

(b) Upon the request of Agent, each Grantor shall execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as Agent may reasonably request to evidence Agent’s security interest in any IP Collateral and the goodwill of any Grantor relating thereto or represented thereby (including, without limitation, filings with the United States Patent and Trademark Office or any similar office), and each Grantor hereby constitutes Agent as its attorney-in-fact to execute and file all such writings for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed; provided, however, that Agent’s taking of such action shall not be a condition to the creation or perfection of the security interest created hereby.

**7. Grantors’ Rights to Enforce Intellectual Property.** Prior to Agent’s giving of notice to Grantors following the occurrence and during the continuance of an Event of Default, Grantors shall have the exclusive right to sue for past, present and future infringement of the IP Collateral, including the right to seek injunctions and/or money damages, in an effort by Grantors to protect the IP Collateral against encroachment by third parties, provided, however, that:

(a) Any money damages awarded or received by Grantors on account of such suit (or the threat of such suit) shall constitute IP Collateral.

(b) Any damages recovered in any action pursuant to this Section, net of costs and attorneys’ fees reasonably incurred, shall be applied in accordance with the Credit Agreement and the Guarantee and Collateral Agreement.

(c) Following the occurrence and during the continuance of any Event of Default, Agent, by notice to any Grantor may terminate or limit such Grantor’s rights under this Section 7.

**8. Agent’s Actions to Protect Intellectual Property.** Pursuant to and in accordance with the Credit Agreement, Agent, acting in its own name or in that of any Grantor, may (but shall not be required to) act in such Grantor’s place and stead and/or in Agent’s own right with respect to the rights and obligations of such Grantor under Section 3, Section 6 and Section 7 hereof.

**9. Rights Upon Default.** Upon the occurrence and during the continuance of any Event of Default, Agent may exercise all rights and remedies as provided for in the Credit Agreement.

**10. Agent as Attorney In Fact.**

(a) Each Grantor hereby irrevocably constitutes and designates Agent as its attorney-in-fact to:

(i) Following the occurrence and during the continuance of an Event of Default, supplement and amend from time to time Schedule I of this Agreement to include any new or additional Intellectual Property of such Grantor.

- (ii) Exercise any of the rights and powers referenced herein in accordance with this Agreement.
- (b) The grant of a power of attorney, being coupled with an interest, shall be irrevocable until the Obligations are paid in full.
- (c) Agent shall not be obligated to do any of the acts or to exercise any of the powers authorized by Section 8, Section 9 or Section 10 of this Agreement, but if Agent elects to do any such act or to exercise any of such powers, it shall not be accountable for more than it actually receives as a result of such exercise of power, and shall not be responsible to any Grantor for any act or omission to act, except to the extent Agent acted with gross negligence or willful misconduct as determined by a court of competent jurisdiction.

11. **Agent's Rights.** Upon an Event of Default and during the continuance thereof, any use by Agent of the IP Collateral, as authorized hereunder in connection with the exercise of Agent's rights and remedies under this Agreement and under the Credit Agreement shall be coextensive with Grantors' rights thereunder and with respect thereto and without any liability for royalties or other related charges.

12. **No Limitation; Loan Documents.** This Agreement has been executed and delivered by each Grantor for the purpose of recording the security interest granted to Agent with respect to the IP Collateral with the United States Patent and Trademark Office, the United States Copyright Office, as well as with any similar office or department of any other foreign or domestic Governmental Authority. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Agent, for the benefit of Lender, under the Guarantee and Collateral Agreement and the other Loan Documents. The other Loan Documents (and all rights and remedies of Grantors, Agent, and Lenders thereunder) shall remain in full force and effect in accordance with their terms.

13. **Termination; Release of Trademark Collateral.** This Agreement and all obligations of each Grantor and Agent hereunder shall terminate on the date upon which the Obligations are performed in full and paid in full. Upon termination of this Agreement, Agent shall, at the expense of the Grantors, take such actions required by the Credit Agreement or the Guarantee and Collateral Agreement or as otherwise reasonably requested by Grantors to release its security interest in the IP Collateral.

14. **Binding Effect; Benefits.** This Agreement shall be binding upon each Grantor and its successors and assigns, and shall inure to the benefit of Agent, Lenders and their respective successors and assigns.

15. **GOVERNING LAW.**

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO ITS CHOICE OF LAW PROVISIONS THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION.

16. **Copy of Agreement.** Each Grantor acknowledges receipt of a signed copy of this Agreement.

*[Remainder of page intentionally blank; signature page follows.]*

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be executed by its duly authorized representatives as of the date first above written.

**GRANTORS:**

**PDI, INC.,**  
a Delaware corporation

By: \_\_\_\_\_ *Nancy Lurker* \_\_\_\_\_  
Name: Nancy S. Lurker  
Title: Chief Executive Officer

**GROUP DCA, LLC,**  
a Delaware limited liability company

By: \_\_\_\_\_ *Nancy Lurker* \_\_\_\_\_  
Name: Nancy S. Lurker  
Title: Chief Executive Officer

**INTERPACE DIAGNOSTICS, LLC,**  
a Delaware limited liability company

By: \_\_\_\_\_ *Nancy Lurker* \_\_\_\_\_  
Name: Nancy S. Lurker  
Title: Chief Executive Officer

**JS GENETICS, INC.,**  
a Delaware corporation

By: \_\_\_\_\_ *Nancy Lurker* \_\_\_\_\_  
Name: Nancy S. Lurker  
Title: Chief Executive Officer

[Signature Page to Intellectual Property Security Agreement]

#33012784

**TRADEMARK**  
**REEL: 005394 FRAME: 0294**



AGENT:

SWK FUNDING LLC,  
a Delaware limited liability company

By:   
Name: Winstop Black  
Title: Managing Director

**INTELLECTUAL PROPERTY**

**Copyrights**

*none*

**Patents**

**U.S. cases:**

<b>Owner</b>	<b>App. No. Patent No.</b>	<b>Filing Date Issue Date</b>	<b>Title</b>	<b>Country</b>
Interpace Diagnostics	60/826,173 NA	09/19/2006 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	US
Interpace Diagnostics	11/857,948 NA	9/19/2007 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	US
Interpace Diagnostics	61/414,778 NA	11/17/2010 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	US
Interpace Diagnostics	13/299,226 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	US
Interpace Diagnostics	61/534,332 NA	09/13/2011 NA	Methods and Compositions Involving miR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease	US
Interpace Diagnostics	61/536,486 NA	09/19/2011 NA	Methods and Compositions Involving miR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease	US
Interpace Diagnostics	13/615,066 NA	9/13/2012 NA	Methods and Compositions Involving miR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease	US
Interpace Diagnostics	61/552,451 NA	10/27/2011 NA	miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors	US
Interpace Diagnostics	61/552,762 NA	10/27/2011 NA	miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors	US
Interpace Diagnostics	13/662,450 NA	10/27/2012 NA	miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors	US
Interpace Diagnostics	61/709,411 NA	10/04/2012 NA	Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions	US
Interpace Diagnostics	61/716,396 NA	10/19/2012 NA	Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions	US
Interpace Diagnostics	13/801,737 NA	3/13/2013 NA	Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions	US
PDI, Inc.	13/436,259	3/30/2012	Consolidated Presentation Of Pharmaceutical Information From Multiple Sources	US
JS Genetics Inc.	13/266434	4/28/2010	Molecdular Diagnosis of Fragile X Syndrome Associated with FMR1 Gene	US
JS Genetics Inc.	13/266429	4/26/2010	Method of Prenatal Molecular Diagnosis of Down Syndrome and Other Trisomic Disorders	US

**Foreign Cases:**

<b>Owner</b>	<b>App. No. Patent No.</b>	<b>Filing Date Issue Date</b>	<b>Title</b>	<b>Country</b>
Interpace Diagnostics	PCT/US07/78936 NA	09/19/2007 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	PCT
Interpace Diagnostics	2007299828 NA	9/19/2007 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	AU
Interpace Diagnostics	2,664,383 NA	9/19/2007 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	CA
Interpace Diagnostics	12159733 NA	9/19/2007 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	EU
Interpace	2009-529373	9/19/2007	MicroRNAs Differentially Expressed in	JP



Owner	App. No. Patent No.	Filing Date Issue Date	Title	Country
Diagnostics	5520605	4/11/2014	Pancreatic Disease and Uses Thereof	
Interpace Diagnostics	PCT/US11/61237 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	PCT
Interpace Diagnostics	2011329772 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	AU
Interpace Diagnostics	1120130122650 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	BR
Interpace Diagnostics	2817882 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	CA
Interpace Diagnostics	14150739.2 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	EU
Interpace Diagnostics	226356 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	IL
Interpace Diagnostics	2013540026 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	JP
Interpace Diagnostics	PCT/US2012/062330 NA	10/27/2012 NA	miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors	PCT
Interpace Diagnostics	12787991.4 NA	10/27/2012 NA	miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors	EU
Interpace Diagnostics	PCT/US2013/030990 NA	3/13/2013 NA	Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions	PCT
PDI, Inc.	PCT/US2013/034670	3/29/2013	Consolidated Presentation Of Pharmaceutical Information From Multiple Sources	PCT

### Co-owned Patent Applications

Owner	App. No. Patent No.	Filing Date Issue Date	Title	Country
Interpace Diagnostics & Brigham Women's Hospital	13/801,737 NA	3/13/2013 NA	Diagnostic Mirnas For Differential Diagnosis Of Incidental Pancreatic Cystic Lesions	US
Interpace Diagnostics & Brigham Women's Hospital	PCT/US2013/030990 NA	3/13/2013 NA	Diagnostic Mirnas For Differential Diagnosis Of Incidental Pancreatic Cystic Lesions	PCT

### Trademarks

Owner	Mark	Country	App. No. Reg. No.
Interpace Diagnostics	MIRINFORM	US	77/447,187 3,546,361
Interpace Diagnostics	MIRINFORM	US	85/067,844 4,071,426
Interpace Diagnostics	MIRINFORM	US	85/067,850 4,071,427
Interpace Diagnostics	MIRINFORM	MP (CN)	A0035669 1162299
Interpace Diagnostics	MIRINFORM	MP (CN)	A0035671 11621785
Group DCA, LLC	DIAGRAM	US	85/145,671 3,970,284
Group DCA, LLC	CUECARD	US	78/826,562 3,486,366
Group DCA, LLC	PD ONE	US	85/567,143 4,593,300
Group DCA, LLC	PD ONE	US	85/567,130 4,593,299
Interpace Diagnostics, LLC	BaraGen	US	86/390,390 n/a
Interpace Diagnostics, LLC	THYMIRA	US	86/370,332 n/a
Interpace Diagnostics, LLC	THYRAMIR	US	86/370,328 n/a
Interpace Diagnostics, LLC	PancraGEN	US	86/370,325 n/a
Interpace Diagnostics, LLC	ThyGenX	US	86/365,003 n/a
Interpace Diagnostics, LLC	PANCRAMIR	US	86/357,914 n/a
Interpace Diagnostics LLC		US	86/290,079 n/a
Interpace	POWER IN	US	86/325,980

Owner	Mark	Country	App. No. Reg. No.
Diagnostics LLC	PERFORMANCE		n/a
PDI, Inc.	INTERPACE DIAGNOSTICS	US	86/130,866 n/a
PDI, Inc.		US	76/630,045 3,617,915
PDI, Inc.		US	76/630,047 3,344,703
PDI, Inc.	PDI	US	76/630,046 3,617,916
PDI, Inc.	PD ONE REP	US	86/227,209 n/a
PDI, Inc.	THE MEDICAL BUZZ	US	85/930,489 4465320
PDI, Inc.	THE MEDICAL BAG	US	85/929,050 n/a
PDI, Inc.	WHAT KILLED 'EM	US	85/930,510 4,465,321
PDI, Inc.	DESPICABLE DOCTORS	US	85/930,412 4465315
PDI, Inc.	COMIC SEIZURE	US	85/930,420 4465316
PDI, Inc.	HCP ECOSYSTEM	US	85/971374 n/a
PDI, Inc.	INTERPACE DIAGNOSTICS	US	86/130866

**Mask Works**

*none*